Article Text

Download PDFPDF

Fucosylation enhances activity of cytotoxic T lymphocytes against breast cancer
  1. Na Qiao1,
  2. Elizabeth A Mittendorf1,
  3. Mao Zhang1,
  4. Pariya Sukhumalchandra1,
  5. Jodie L Polan1,
  6. Samantha Neal1,
  7. Mikael Rauf1,
  8. Victor Gall1,
  9. Anne V Philips1,
  10. Elizabeth J Shpall1 and
  11. Gheath Alatrash1
  1. Aff1 grid.240145.60000000122914776The University of Texas MD Anderson Cancer Center Houston TX USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Fucosylation is a process by which fucose sugar groups are added to cell surface receptors. This process is mediated by fucosyl transferases that attach terminal fucose groups to acceptor molecules on the cell surface. Fucosylation of cord blood stem cells and human regulatory T cells (Treg) were shown to enhance cord blood engraftment and Treg homing to inflamed tissues. Since tumor tissues have a component of inflammation, we hypothesized that fucosylation of antigen specific cytotoxic T lymphocytes (CTL) ex vivo will enhance their migration into tumors and subsequent killing of tumor cells. Specifically we tested whether ex vivo fucosylation of CTL that target the HLA-A2 restricted HER2/neu-derived peptide, E75, enhances E75-CTL migration and cytotoxic functions.


E75-CTL were generated using standard methodologies. Fucosylation was achieved by co-culturing T cells with FTVII enzyme (Targazyme) and GDP fucose. To study migration, fucosylated and non-fucosylated E75-CTL were passed through chambers that were coated with a HUVEC barrier and migrated CTL were detected using cell fluorescence. To examine CTL surface markers, cells were stained for standard co-stimulatory and adhesion molecules and were analyzed using flow cytometry. Calcein AM cytotoxicity assays were used to determine the effects of fucosylation on CTL killing of target cells. For in vivo assessment of fucosylation on activity of CTL, NSG mice were engrafted orthotopically with SKBR3-A2 human breast cancer cells and were treated with intravenous injections of 106 fucosylated or non-fucosylated E75-CTL. Mice were examined twice weekly and were sacrificed on week 5 for tissue analysis.


Fucosylated E75-CTL showed 1.6-fold higher migration through the HUVEC cell barrier compared to non-fucosylated E75-CTL (MFI=14,264 vs. 8,926). Analysis of T cell surface expression of chemokine/adhesion molecules showed approximately a 5-fold increase in CD49d and CD195, and 50% increase in CXCR1 and CXCR3 following fucosylation. Fucosylation enhanced the cytotoxicity of E75-CTL against E75-pulsed T2 targets (cytotoxicity=33% vs. 25%). In vivo experiments using SKBR3-A2 breast cancer xenografts showed that fucosylated E75-CTL reduced SKBR3-A2 tumor size by 20%, in comparison with 5% reduction in the tumor size by non-fucosylated E75-CTL. Lastly, flow cytometry showed a 2-fold increase in the frequency of human CD45+ lymphocytes in the primary tumor following fucosylation.


Fucosylation enhances the migration and cytotoxic functions of E75-CTL. Our data demonstrate a novel approach to enhance the efficacy of antigen specific T cells that could be used in adoptive cellular immunotherapy approaches for breast cancer.